Escitalopram and outcomes among patients with depression and heart failure

JAMA - Journal of the American Medical Association

Volumn 316, Issue 14, 2016, Pages 1494-

  Ströhle, Andreas ^a   Rieckmann, Nina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

CAUSE OF DEATH; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HOSPITALIZATION; HUMAN; LETTER; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; TREATMENT OUTCOME;

CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HEART FAILURE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84997481979     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.13855     Document Type: Letter

References (4)

1. Angermann CE, Gelbrich G, Störk S, et al; MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA. 2016;315(24):2683-2693.
2. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: ameta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
3. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-levelmeta-analysis. JAMA. 2010;303(1):47-53.
4. Posternak MA, Miller I. Untreated short-term course of major depression: ameta-analysis of outcomes from studies using wait-list control groups. J Affect Disord. 2001;66(2-3):139-146.